QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake

Analysts have lifted the uniQure fair value estimate from about $52.56 to $64.47, citing recent FDA feedback on AMT-130 that, in their view, improves visibility on a potential accelerated approval path and supports higher modeled revenue growth with a lower assumed discount rate and P/E multiple.

Analyst Commentary

Recent Street research on uniQure has shifted sharply following the latest FDA Type B meeting on AMT-130, with multiple firms revising price targets and ratings after the company outlined plans for a potential accelerated approval filing. For you as an investor, the key story is how this regulatory feedback is feeding into higher modeled value for uniQure, while still leaving room for execution and regulatory risk around Huntington's disease.

Bullish Takeaways

• Bullish analysts point to the FDA's willingness to accept three-year Phase 1/2 data for AMT-130 as the primary basis for a biologics license application. They see this as removing a major regulatory overhang and supporting higher valuation assumptions for uniQure.
• Several research notes describe AMT-130 as having one of the clearest potential accelerated approval paths in Huntington's disease. This view feeds into higher price targets in the US$60 to US$80 range as analysts factor earlier potential revenue contribution into their models.
• Some bullish analysts frame Huntington's disease as a large commercial opportunity for uniQure. One report cites a US$3b-plus peak sales scenario for the indication, which they compare directly with the company's current market value to argue for upside potential.
• Goldman Sachs and other bullish analysts highlight that the FDA feedback has shifted attention away from regulatory uncertainty and toward future drivers such as confirmatory study design, durability data and eventual review outcomes, which are now being incorporated into their long-term growth and P/E assumptions.

Bearish Takeaways

• Even with sharply higher targets, some cautious analysts maintain more neutral ratings. This signals that they see improved visibility for uniQure but still view the risk and reward as more balanced until there is greater clarity on confirmatory trial results and longer term follow up.
• Several reports note that timelines for a full regulatory process and commercial ramp in Huntington's disease remain extended. This can limit near term cash flow visibility for uniQure even as sentiment improves.
• A few research notes emphasize that, while the FDA's stance has turned more permissive, eventual regulatory review and post approval commitments could still influence the pace and scale of value realization for uniQure. This leaves room for volatility if upcoming data or interactions are less favorable than current expectations.
• The reliance on early stage data for a potential accelerated approval filing means that uniQure still needs to execute cleanly on future studies and durability readouts. Any setback on these fronts could pressure the higher valuation levels implied by recent target changes.

What’s in the News for uniQure

• uniQure plans to submit a Biologics License Application in Q3 2026 for AMT-130 in Huntington’s disease, after the FDA indicated that three year Phase I/II data can serve as the primary basis for an accelerated approval filing, with discussions ongoing to finalize a confirmatory study using concurrent standard of care controls. Source: company announcement, FDA Type B meeting summary.
• The company reported that AMT-130 holds Regenerative Medicine Advanced Therapy, breakthrough therapy and fast track designations from the FDA, reinforcing its status as a potential first gene therapy for Huntington’s disease. Source: AMT-130 regulatory update.
• uniQure initiated a US$150m underwritten public offering of ordinary shares and pre funded warrants, with an option for underwriters to purchase an additional US$22.5m, to support commercialization readiness and a confirmatory study for AMT-130 ahead of the planned 2026 BLA submission. Source: public offering announcement.
• The company closed an upsized equity offering, raising about US$259m in gross proceeds at US$45.50 per share, with plans to allocate funds toward potential AMT-130 launches, development of other clinical candidates and general corporate purposes. Source: follow on offering closing announcement.
• uniQure released six month data from the low dose cohort in its Phase I/IIa trial of AMT-260 in refractory mesial temporal lobe epilepsy, reporting that three of six patients had meaningful reductions in disabling seizures and that the therapy was generally well tolerated without treatment related serious adverse events or required immunosuppression. Source: AMT-260 clinical update.

Valuation Changes for uniQure

• Fair Value: updated analyst fair value estimate has risen from $52.56 to $64.47.
• Discount Rate: assumed discount rate has fallen slightly from 7.40% to about 7.28%.
• Revenue Growth: modeled long term revenue growth rate has increased from about 137% to about 175%, indicating a higher growth profile is being used in forecasts for uniQure.
• Net Profit Margin: projected net profit margin has been adjusted marginally from about 18.98% to about 18.92%.
• Future P/E: future P/E multiple has been reduced from about 109x to about 86x, suggesting analysts are now assigning a lower valuation multiple to uniQure's projected earnings.